BioLineRx (BLRX) Q4 2025 earnings summary

Executive summary

• Advanced GLIX1, a first-in-class oral molecule for glioblastoma, into clinical development with phase I/II-A trial initiation expected by end of March 2026 and patient treatment to begin soon.

• GLIX1 granted orphan drug designation by FDA and EMA, offering expedited review and exclusivity benefits.

• Motixafortide development in pancreatic cancer continues, with accelerated enrollment in the phase IIb Chemo4METPANC trial and interim analysis expected in 2026.

• Positive phase I results for motixafortide in sickle cell disease, showing robust stem cell mobilization and safety.

• Legal dispute with Biokine Therapeutics resolved in favor of the company, removing a $7.2 million financial overhang.

Financial highlights

• 2025 revenues were $1.2 million, down from $28.9 million in 2024, primarily reflecting royalties from APHEXDA sales.

• Research and development expenses decreased to $8.1 million from $9.2 million year-over-year, mainly due to motixafortide out-licensing and lower headcount.

• General and administrative expenses fell to $3.1 million from $6.3 million, driven by reversal of a doubtful accounts provision and reduced payroll.

• Net loss narrowed to $2 million from $9.2 million in 2024.

• Year-end cash and equivalents totaled $20.9 million, sufficient to fund operations into the first half of 2027.

Outlook and guidance

• GLIX1 phase I/II-A trial to begin imminently, with phase I data expected in the first half of 2027.

• Chemo4METPANC interim/futility analysis anticipated in 2026; positive results could be a significant value inflection point.

• Ongoing preclinical work for GLIX1 in additional cancer indications and combination studies with PARP inhibitors.

• Royalties and milestone-driven revenue expected from Ayrmid and Gloria Biosciences agreements.

• Cash runway expected to fund operations into the first half of 2027.